JP2010516708A - 抗体結合体の使用 - Google Patents

抗体結合体の使用 Download PDF

Info

Publication number
JP2010516708A
JP2010516708A JP2009546582A JP2009546582A JP2010516708A JP 2010516708 A JP2010516708 A JP 2010516708A JP 2009546582 A JP2009546582 A JP 2009546582A JP 2009546582 A JP2009546582 A JP 2009546582A JP 2010516708 A JP2010516708 A JP 2010516708A
Authority
JP
Japan
Prior art keywords
cancer
antibody
mab
fragment
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2009546582A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010516708A5 (OSRAM
Inventor
リチャード エイチ． ウェイスバート
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Government of the United States of America
Original Assignee
Government of the United States of America
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Government of the United States of America filed Critical Government of the United States of America
Publication of JP2010516708A publication Critical patent/JP2010516708A/ja
Publication of JP2010516708A5 publication Critical patent/JP2010516708A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1758—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals p53
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
JP2009546582A 2007-01-22 2008-01-22 抗体結合体の使用 Pending JP2010516708A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US89701207P 2007-01-22 2007-01-22
PCT/US2008/051734 WO2008091911A2 (en) 2007-01-22 2008-01-22 Use of antibody conjugates

Publications (2)

Publication Number Publication Date
JP2010516708A true JP2010516708A (ja) 2010-05-20
JP2010516708A5 JP2010516708A5 (OSRAM) 2012-03-01

Family

ID=39645132

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009546582A Pending JP2010516708A (ja) 2007-01-22 2008-01-22 抗体結合体の使用

Country Status (6)

Country Link
US (2) US20100143358A1 (OSRAM)
EP (1) EP2109625A4 (OSRAM)
JP (1) JP2010516708A (OSRAM)
AU (1) AU2008207948A1 (OSRAM)
CA (1) CA2676234A1 (OSRAM)
WO (1) WO2008091911A2 (OSRAM)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014513069A (ja) * 2011-04-01 2014-05-29 イェール ユニバーシティー 細胞浸透性抗ｄｎａ抗体およびｄｎａ修復を阻害するためのその使用
JP2017503511A (ja) * 2014-01-13 2017-02-02 バレリオン セラピューティクス， エルエルシー 内在化部分

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9539327B2 (en) * 2007-11-26 2017-01-10 The Research Foundation For The State University Of New York Small molecule cancer treatments that cause necrosis in cancer cells but do not affect normal cells
WO2010044894A1 (en) 2008-10-15 2010-04-22 4S3 Bioscience Inc. Methods and compositions for treatment of myotonic dystrophy
CA2799608C (en) * 2009-05-28 2023-02-28 Richard H. Weisbart Amino acid sequences which enhance peptide conjugate solubility
WO2010148010A1 (en) 2009-06-15 2010-12-23 4S3 Bioscience Inc. Methods and compositions for treatment of myotubular myopathy using chimeric polypeptides comprising myotubularih 1 (mtm1) polypeptides
US20140079698A1 (en) * 2011-04-07 2014-03-20 Memorial Sloan Kettering Cancer Center Anti-tumor antibody-tumor suppressor fusion protein compositions and methods of use for the treatment of cancer
US9610362B2 (en) 2012-03-16 2017-04-04 Valerion Therapeutics, Llc Antisense conjugates for decreasing expression of DMPK
US9283272B2 (en) * 2012-03-30 2016-03-15 The United States Of America As Represented By The Department Of Veterans Affairs Targeting intracellular target-binding determinants with intracellular antibodies
US12195550B2 (en) * 2012-03-30 2025-01-14 The United States Of America As Represented By The Department Of Veterans Affairs Targeting intracellular target-binding determinants with intracellular antibodies
WO2013177428A1 (en) * 2012-05-23 2013-11-28 Valerion Therapeutics, Inc. Methods for increasing muscle contractility
WO2014130723A1 (en) 2013-02-20 2014-08-28 Valerion Therapeutics, Llc Methods and compositions for treatment of pompe disease
US10040867B2 (en) 2014-03-04 2018-08-07 Yale University Cell penetrating anti-guanosine antibody based therapy for cancers with Ras mutations
US10238742B2 (en) 2014-06-25 2019-03-26 Yale University Cell penetrating nucleolytic antibody based cancer therapy
AU2015308894A1 (en) 2014-08-27 2017-03-23 Valerion Therapeutics, Llc Internalizing moieties for treatment of cancer
JP6599566B2 (ja) 2015-10-08 2019-10-30 ユニバーシティー オブ ユタ リサーチ ファウンデーション がんを予防又は治療する方法及び組成物
US11016085B2 (en) 2016-04-25 2021-05-25 The Johns Hopkins University ZNT8 assays for drug development and pharmaceutical compositions
WO2017218824A1 (en) 2016-06-15 2017-12-21 Yale University Anti-guanosine antibody as a molecular delivery vehicle
EP3471777A1 (en) 2016-06-15 2019-04-24 Yale University Antibody-mediated autocatalytic, targeted delivery of nanocarriers to tumors
US11892457B2 (en) 2017-07-12 2024-02-06 The Johns Hopkins University Proteoliposome-based ZnT8 self-antigen for type 1 diabetes diagnosis
WO2019152806A1 (en) * 2018-02-01 2019-08-08 Yale University Compositions and methods for enhancing nuclear translocation
WO2019195851A1 (en) 2018-04-06 2019-10-10 Oncolyze, Inc. Compositions for use in lysis of selective cancer cells
EP3837286A4 (en) 2018-08-16 2022-08-10 The Johns Hopkins University ANTIBODIES TO HUMAN ZNT8
AU2019331009A1 (en) 2018-08-31 2021-03-18 Yale University Compositions and methods for enhancing donor oligonucleotide-based gene editing
MX2022002342A (es) 2019-08-30 2022-06-14 Univ Yale Composiciones y metodos para suministro de acidos nucleicos a celulas.
US12366570B2 (en) 2019-10-01 2025-07-22 The Johns Hopkins University Cell-based ZNT8 assay
EP4387666A4 (en) * 2021-08-20 2025-07-16 Univ Johns Hopkins CELL SURFACE ANTIBODY FOR A PANCREATIC BETA CELL SPECIFIC BIOMARKER

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4812397A (en) * 1987-02-10 1989-03-14 The Regents Of The University Of California MAB-anti-DNA related to nephritis
WO1997032602A1 (en) * 1996-03-08 1997-09-12 The Regents Of The University Of California DELIVERY SYSTEM USING mAb 3E10 AND MUTANTS AND/OR FUNCTIONAL FRAGMENTS THEREOF
US6485977B1 (en) * 1999-09-13 2002-11-26 Cornell Research Foundation, Inc. Recombinant constructs and techniques for delivering to eucaryotic cells bacterial proteins that are secreted via type III secretion systems

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
JPN6013005895; Ｊ．Ｅ．　Ｈａｎｓｅｎ　ｅｔ　ａｌ: Ｊｏｕｒｎａｌ　ｏｆ　Ｉｎｖｅｓｔｉｇａｔｉｖｅ　Ｍｅｄｉｃｉｎｅ ｖｏｌ．５５，　ｎｏ．１，　Ｓｕｐｐｌ．　Ｓ, 20070101, ｐ．Ｓ９２-Ｓ９３ *
JPN6013005897; Ｒｉｃｈａｒｄ　Ｈ．　Ｗｅｉｓｂａｒｔ　ｅｔ　ａｌ: Ｉｎｔｅｒｎａｔｉｏｎａｌ　Ｊｏｕｒｎａｌ　ｏｆ　Ｏｎｃｏｌｏｇｙ ２５（６）, 200412, ｐ．１８６７-１８７３ *
JPN6013005899; Ｒｉｃｈａｒｄ　Ｈ．　Ｗｅｉｓｂａｒｔ　ｅｔ　ａｌ: Ｃａｎｃｅｒ　Ｌｅｔｔｅｒｓ １９５（２）, 20030610, ｐ．２１１-２１９ *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014513069A (ja) * 2011-04-01 2014-05-29 イェール ユニバーシティー 細胞浸透性抗ｄｎａ抗体およびｄｎａ修復を阻害するためのその使用
JP2016094479A (ja) * 2011-04-01 2016-05-26 イェール ユニバーシティーＹａｌｅ Ｕｎｉｖｅｒｓｉｔｙ 細胞浸透性抗ｄｎａ抗体およびｄｎａ修復を阻害するためのその使用
JP2017503511A (ja) * 2014-01-13 2017-02-02 バレリオン セラピューティクス， エルエルシー 内在化部分

Also Published As

Publication number Publication date
US20100143358A1 (en) 2010-06-10
CA2676234A1 (en) 2008-07-31
WO2008091911A3 (en) 2008-11-06
EP2109625A2 (en) 2009-10-21
WO2008091911A8 (en) 2008-12-18
US20170096497A1 (en) 2017-04-06
WO2008091911A2 (en) 2008-07-31
EP2109625A4 (en) 2011-06-08
AU2008207948A1 (en) 2008-07-31

Similar Documents

Publication Publication Date Title
JP2010516708A (ja) 抗体結合体の使用
JP4672092B2 (ja) 細胞アポトーシスを阻害するタンパク質であるサービビン（Ｓｕｒｖｉｖｉｎ）、およびその調節
JP6728264B2 (ja) 抗ｈｅｒ２抗体及びその結合体
JP6734227B2 (ja) 抗ｃｄ２７６抗体（ｂ７ｈ３）
USRE46211E1 (en) Delivery system using MAB 3E10 and mutants and/or functional fragments thereof
EP1895005B1 (en) Cell-permeable peptide inhibitors of the JNK signal transduction pathway
EP1979379B1 (en) Carbonic anhydrase ix (g250) antibodies and methods of use thereof
KR101960004B1 (ko) Cldn6 생체내 표적-지향된 항체를 이용하는 암 치료법
JP6643244B2 (ja) 補体因子Ｂｂ抗体
JP2008520186A (ja) 哺乳類ｅａｇ１イオンチャネルタンパク質に対する新規の抗体
RS51898B (sr) Specifični agensi koji vezuju humani angiopoetin-2
US8273550B2 (en) Antibodies against a cancer-associated epitope of variant HnRNPG and uses thereof
CN102459344A (zh) 抗axl抗体
KR20140033391A (ko) 면역원성이 보다 낮은 t 세포 및/또는 b 세포 에피토프를 갖는 슈도모나스 외독소 a
JP2008508903A (ja) 腫瘍特異的抗体
WO1999035170A9 (en) Compositions and methods for the treatment of tumor
JP4766716B2 (ja) ＰｃｒＶに対する抗体
JP2013541944A (ja) 腫瘍形成（ｎｅｏｐｌａｓｉａ）を治療するための組成物および方法
EA034414B1 (ru) Способ лечения тройного негативного рака молочной железы
CN107207585B (zh) 补体组分c5抗体
US11208494B2 (en) Monoclonal antibodies specific to the plexin-semaphorin-integrin (PSI) domain of RON for drug delivery and its application in cancer therapy
CN113993897B (zh) 抗tie2抗体及其用途
JP2010077026A (ja) がん関連マクロファージを標的とした固形がん治療剤
KR101854529B1 (ko) 인간 및 마우스 Ｓｅｍａ３Ａ에 교차결합하는 항체 및 그의 용도
JP5896568B2 (ja) 動脈硬化又は動脈硬化性疾患の治療剤、及び動脈硬化又は動脈硬化性疾患の診断薬

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110121

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20110121

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120110

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130213

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130501

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130510

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130611

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20130807